Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Ribupatide

Stage Phase 3Stale

Sponsor Fujian Shengdi Pharmaceutical Co

Route oral and injection

Class GLP-1/GIP

Mechanism dual GLP-1 and GIP receptor agonist

Sources

registry, as of 2026-10-06Stale

https://clinicaltrials.gov/study/NCT07284875

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Kailera. Enrollment 2530. Conditions Obesity; Overweight. The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

ClinicalTrials.gov NCT07284875 protocol and results modules

registry, as of 2026-10-06Stale

https://clinicaltrials.gov/study/NCT07284901

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Kailera. Enrollment 1270. Conditions Obesity With Diabetes; Overweight With Diabetes. The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)

ClinicalTrials.gov NCT07284901 protocol and results modules

registry, as of 2026-08-13Stale

https://clinicaltrials.gov/study/NCT07670884

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects. Overall status RECRUITING. Phases PHASE3. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 675. Conditions Chronic Management of Body Weight. This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.

ClinicalTrials.gov NCT07670884 protocol and results modules

registry, as of 2025-07-11Stale

https://clinicaltrials.gov/study/NCT06396429

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese. Overall status COMPLETED. Phases PHASE3. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 567. Conditions Overweight or Obesity. The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.

ClinicalTrials.gov NCT06396429 protocol and results modules

registry, as of 2026-07-17Stale

https://clinicaltrials.gov/study/NCT07709910

A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 382. Conditions Participants With Obesity and Knee Osteoarthritis. The study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.

ClinicalTrials.gov NCT07709910 protocol and results modules

registry, as of 2026-11-04

https://clinicaltrials.gov/study/NCT06994650

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 144. Conditions Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy. This study is a phase 3 clinical trial, aiming to evaluate the efficacy and safety of HRS-9531 injection in obese subjects with obstructive sleep apnea (OSA) who are on positive airway pressure ventilation (PAP) therapy.

ClinicalTrials.gov NCT06994650 protocol and results modules

registry, as of 2025-11-17Stale

https://clinicaltrials.gov/study/NCT06974851

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 140. Conditions Bstructive Sleep Apnea (OSA) and Obesity. A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects with Obstructive Sleep Apnea (OSA) and Obesity

ClinicalTrials.gov NCT06974851 protocol and results modules

registry, as of 2026-07-15Stale

https://clinicaltrials.gov/study/NCT07458269

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Kailera. Enrollment 264. Conditions Obesity. The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

ClinicalTrials.gov NCT07458269 protocol and results modules

registry, as of 2026-10-22Stale

https://clinicaltrials.gov/study/NCT05881837

A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes. Overall status COMPLETED. Phases PHASE2. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 249. Conditions Overweight or Obesity. This study aims to evaluate the efficacy and dose-response relationship of HRS9531 injection compared with placebo in reducing body weight in obese subjects without diabetes after 24 weeks of treatment.

ClinicalTrials.gov NCT05881837 protocol and results modules

registry, as of 2025-11-24Stale

https://clinicaltrials.gov/study/NCT06391710

HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 203. Conditions Heart Failure With Preserved Ejection Fraction. This was a multicenter, randomized, double-blind, placebo-parallel-controlled Phase II clinical study to evaluate the efficacy and safety of HRS9531 Injection compared to placebo in obese subjects with heart failure with preserved ejection fraction. A total of 200 obese subjects

ClinicalTrials.gov NCT06391710 protocol and results modules

publication, as of 2026-11-03

https://pubmed.ncbi.nlm.nih.gov/42764407/

clinical pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ribupatide (HRS9531), a novel dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Preclinical assessments of ribupatide included in vitro functional recept

PMID 42764407

Studies

KaiNETIC-1

Registry NCT07284875

Phase Phase 3

Status Active, not recruiting

Enrollment 2530

Start 2025-12-18

Ribupatide: Dose 1

Regimen once weekly

Comparator placebo

Population Obesity; Overweight

Ribupatide: Dose 2

Regimen once weekly

Comparator placebo

Population Obesity; Overweight

Ribupatide: Dose 3

Regimen once weekly

Comparator placebo

Population Obesity; Overweight

Ribupatide: Dose 4

Regimen once weekly

Comparator placebo

Population Obesity; Overweight

Placebo

Regimen once weekly

Population Obesity; Overweight

KaiNETIC-2

Registry NCT07284901

Phase Phase 3

Status Active, not recruiting

Enrollment 1270

Start 2026-01-12

Primary completion 2028-03-27

Study completion 2028-04-24

Catalyst Primary completion. 2028-03-27. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Ribupatide: Dose 1

Regimen once weekly

Comparator placebo

Population Obesity With Diabetes; Overweight With Diabetes

Ribupatide: Dose 2

Regimen once weekly

Comparator placebo

Population Obesity With Diabetes; Overweight With Diabetes

Ribupatide: Dose 3

Regimen once weekly

Comparator placebo

Population Obesity With Diabetes; Overweight With Diabetes

Ribupatide: Dose 4

Regimen once weekly

Comparator placebo

Population Obesity With Diabetes; Overweight With Diabetes

Placebo

Regimen once weekly

Population Obesity With Diabetes; Overweight With Diabetes

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

Registry NCT07670884

Phase Phase 3

Status Recruiting

Enrollment 675

Start 2026-07-24

Primary completion 2027-10-31

Study completion 2027-11-30

Catalyst Primary completion. 2027-10-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

HRS9531 Tablet Group

Comparator placebo

Population Chronic Management of Body Weight

HRS9531 Tablet Placebo Group

Population Chronic Management of Body Weight

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Registry NCT06396429

Phase Phase 3

Status Completed

Enrollment 567

Start 2024-05-13

Primary completion 2025-07-07

Study completion 2025-07-07

Catalyst Primary completion. 2025-07-07. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Treatment group A: HRS9531 injection

Comparator placebo

Population Overweight or Obesity

Treatment group B: HRS9531 injection

Comparator placebo

Population Overweight or Obesity

Treatment group C: HRS9531 injection

Comparator placebo

Population Overweight or Obesity

Placebo injection

Population Overweight or Obesity

A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis

Registry NCT07709910

Phase Phase 3

Status Not yet recruiting

Enrollment 382

Ribupatide Injection

Comparator placebo

Population Participants With Obesity and Knee Osteoarthritis

Placebo

Population Participants With Obesity and Knee Osteoarthritis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apn

Registry NCT06994650

Phase Phase 3

Status Active, not recruiting

Enrollment 144

Start 2025-08-13

HRS9531

Comparator placebo

Population Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy

Placebo

Population Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

Registry NCT06974851

Phase Phase 3

Status Recruiting

Enrollment 140

Start 2025-07-25

Group 1: HRS9531

Comparator placebo

Population Bstructive Sleep Apnea (OSA) and Obesity

Group 2: HRS9531placebo

Population Bstructive Sleep Apnea (OSA) and Obesity

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

Registry NCT07458269

Phase Phase 2

Status Active, not recruiting

Enrollment 264

Start 2026-03-04

Ribupatide: Dose 1

Regimen once weekly

Comparator placebo

Population Obesity

Ribupatide: Dose 2

Regimen once weekly

Comparator placebo

Population Obesity

Ribupatide: Dose 3

Regimen once weekly

Comparator placebo

Population Obesity

Ribupatide: Dose 4

Regimen once weekly

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Population Obesity

A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Registry NCT05881837

Phase Phase 2

Status Completed

Enrollment 249

Start 2023-06-13

Primary completion 2024-10-13

Study completion 2024-10-13

Treatment group A

Comparator placebo

Population Overweight or Obesity

Treatment group B

Comparator placebo

Population Overweight or Obesity

Treatment group C

Comparator placebo

Population Overweight or Obesity

Treatment group D

Comparator placebo

Population Overweight or Obesity

Treatment group E

Population Overweight or Obesity

Treatment group F

Population Overweight or Obesity

Treatment group G

Population Overweight or Obesity

Treatment group H

Population Overweight or Obesity

HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

Registry NCT06391710

Phase Phase 2

Status Active, not recruiting

Enrollment 203

Start 2024-05-06

HRS9531

Comparator placebo

Population Heart Failure With Preserved Ejection Fraction

Placebo

Population Heart Failure With Preserved Ejection Fraction